Intralesional Cryosurgery Feasible for BCC in Elderly

This article originally appeared here.
Share this content:
Intralesional Cryosurgery Feasible for BCC in Elderly
Intralesional Cryosurgery Feasible for BCC in Elderly

TUESDAY, Feb. 23, 2016 (HealthDay News) -- Intralesional cryosurgery is feasible for treating basal cell carcinoma (BCC) of the lower extremities in elderly patients, according to a study published in the March issue of the International Journal of Dermatology.

Yaron Har-Shai, M.D., from the Carmel Medical Center in Haifa, Israel, and colleagues examined the efficacy of intralesional cryosurgery in the treatment of BCC of the lower limbs. Eight patients aged older than 60 years with a total of 10 biopsy-confirmed nodular or superficial BCCs of the lower limbs were enrolled. An intralesional cryosurgery needle (CryoShape) was inserted into the tumor to facilitate its complete freezing using liquid nitrogen. Biopsy taken about three months after complete healing of the cryo-wound was used to confirm treatment success.

The researchers found that lesions were an average of 2.49 cm². The mean recovery time from surgery was 79.9 days. At a mean of 85.3 days after the wound had healed, biopsies were taken; complete tumor destruction was confirmed in all 10 biopsies. Over a follow-up period of 28 months, there was no evidence of wound infection or tumor recurrence.

"This study demonstrates that a single intralesional cryosurgery session can completely eradicate BCC on the lower extremities in elderly patients," the authors write. "This technique is associated with relatively minor complications, is well tolerated, and represents a safe and effective therapeutic modality for BCC of the lower limbs."

One author disclosed financial ties to intralesional cryosurgery technology.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »